OGEN vs. EFTR, VIRI, CANF, BNOX, VAXX, TRVN, HEPA, CVKD, SHPH, and KTTA
Should you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include eFFECTOR Therapeutics (EFTR), Virios Therapeutics (VIRI), Can-Fite BioPharma (CANF), Bionomics (BNOX), Vaxxinity (VAXX), Trevena (TRVN), Hepion Pharmaceuticals (HEPA), Cadrenal Therapeutics (CVKD), Shuttle Pharmaceuticals (SHPH), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical preparations" industry.
eFFECTOR Therapeutics (NASDAQ:EFTR) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, community ranking, analyst recommendations and earnings.
In the previous week, eFFECTOR Therapeutics had 1 more articles in the media than Oragenics. MarketBeat recorded 2 mentions for eFFECTOR Therapeutics and 1 mentions for Oragenics. Oragenics' average media sentiment score of 0.94 beat eFFECTOR Therapeutics' score of 0.00 indicating that eFFECTOR Therapeutics is being referred to more favorably in the media.
Oragenics has lower revenue, but higher earnings than eFFECTOR Therapeutics. Oragenics is trading at a lower price-to-earnings ratio than eFFECTOR Therapeutics, indicating that it is currently the more affordable of the two stocks.
57.7% of eFFECTOR Therapeutics shares are owned by institutional investors. Comparatively, 18.7% of Oragenics shares are owned by institutional investors. 4.7% of eFFECTOR Therapeutics shares are owned by insiders. Comparatively, 24.6% of Oragenics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
eFFECTOR Therapeutics received 23 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 79.31% of users gave eFFECTOR Therapeutics an outperform vote while only 0.00% of users gave Oragenics an outperform vote.
eFFECTOR Therapeutics presently has a consensus price target of $24.00, indicating a potential upside of 1,248.31%. Given Oragenics' higher possible upside, equities research analysts clearly believe eFFECTOR Therapeutics is more favorable than Oragenics.
eFFECTOR Therapeutics has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Comparatively, Oragenics has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500.
Oragenics' return on equity of 0.00% beat eFFECTOR Therapeutics' return on equity.
Summary
eFFECTOR Therapeutics beats Oragenics on 12 of the 16 factors compared between the two stocks.
Get Oragenics News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oragenics Competitors List
Related Companies and Tools
